Krystal(KRYS) - 2024 Q2 - Quarterly Results

Krystal Biotech Announces Second Quarter 2024 Financial Results and Provides Business Updates Net product revenue of $70.3 million in 2Q and$166.2 million since launch in August 2023 On track to deliver three clinical readouts in 2H 2024 Jeune Aesthetics' KB301 Phase 1 PEARL-1 study (Cohorts 3 and 4) in 3Q 2024; KB408 Phase 1 SERPENTINE-1 study for the treatment of AATD in 4Q 2024; and KB707 Phase 1 OPAL-1 study for the treatment of injectable solid tumors in 4Q 2024 Strong balance sheet, ending the quarte ...